SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
Camille Tron 1
Bénédicte Franck 1
Marie-Clémence Verdier 1
Florian Lemaitre 1
Guillaume Bouguen 2
1 Rennes University Hospital, Rennes, France
2 CHU Pontchaillou, Rennes, France
Session
IBD (Posters)
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]